Tag #Biotech

Showing 1 to 12 of 24 results

forbes.com

🌐 85% Global Worthiness

Aug 21, 22:23

Colossal Founders Launch Secretive \$30 Million AI Startup, Astromech

Ben Lamm and George Church, founders of Colossal Biosciences, launched a secretive AI startup called Astromech, raising \$30 million in August 2025, with a mission to "navigate the code of life" using advanced AI technologies.

Colossal Founders Launch Secretive \$30 Million AI Startup, Astromech

Ben Lamm and George Church, founders of Colossal Biosciences, launched a secretive AI startup called Astromech, raising \$30 million in August 2025, with a mission to "navigate the code of life" using advanced AI technologies.

Progress

48% Bias Score

ShareSaveArticle

Industry, Innovation, and Infrastructure

12345678

Previous 1 of 8 Next

What are the immediate implications of Lamm and Church's new AI venture, Astromech, for the biotech industry and broader technological advancements?

Colossal Biosciences founders Ben Lamm and George Church launched Astromech, a secretive AI startup, raising \$30 million. The company's mission statement, "navigating the code of life," and job postings suggest a focus on advanced AI applied to biology.

africa.chinadaily.com.cn

🌐 75% Global Worthiness

Jul 24, 07:15

Hainan's Business-Friendly Policies Attract Biotech Investment

Zeng Sheng, founder of Susheng Biotech in Hainan, secured a 6 million yuan loan and reduced production costs by 20 percent due to Hainan's business-friendly policies, including zero tariffs and streamlined approvals; Hainan's upcoming independent customs operations starting December 18 will further ...

Hainan's Business-Friendly Policies Attract Biotech Investment

Zeng Sheng, founder of Susheng Biotech in Hainan, secured a 6 million yuan loan and reduced production costs by 20 percent due to Hainan's business-friendly policies, including zero tariffs and streamlined approvals; Hainan's upcoming independent customs operations starting December 18 will further ...

Progress

48% Bias Score

ShareSaveArticle

Decent Work and Economic Growth

12345678

Previous 1 of 8 Next

What are the immediate economic impacts of Hainan's business-friendly policies on companies like Susheng Biotech?

Zeng Sheng, founder of Susheng Biotech, established his company in Hainan's Haikou National High-tech Industrial Development Zone, leveraging the area's medical manufacturing infrastructure and preferential policies for overseas-approved drugs. His firm secured a 6 million yuan loan with minimal requirements and reduced production costs by nearly 20 percent due to zero tariffs.

elpais.com

🌐 85% Global Worthiness

Jun 25, 07:17

Tetraneuron's Novel Gene Therapy Targets Alzheimer's Disease by Restoring Neuronal Function

Tetraneuron, based on research from the Cajal Institute in Madrid, is developing a gene therapy for moderate-to-severe Alzheimer's disease by targeting the transcription factor E2F4, showing promising results in animal models and aiming for human trials in 2026.

Tetraneuron's Novel Gene Therapy Targets Alzheimer's Disease by Restoring Neuronal Function

Tetraneuron, based on research from the Cajal Institute in Madrid, is developing a gene therapy for moderate-to-severe Alzheimer's disease by targeting the transcription factor E2F4, showing promising results in animal models and aiming for human trials in 2026.

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the main challenges Tetraneuron faces in transitioning its gene therapy from preclinical studies to human trials?

Unlike existing treatments focusing on amyloid plaques, Tetraneuron's gene therapy seeks to reverse neuronal damage by restoring E2F4 function. Positive results in mice show potential for reversing Alzheimer's, restoring synaptic plasticity crucial for memory formation, a mechanism not addressed by current therapies. This offers a fundamentally different approach to treating the disease.

forbes.com

🌐 85% Global Worthiness

May 13, 16:12

Somite AI Secures \$47 Million to Revolutionize Human Cell Production with AI

Somite AI, a biotech startup, raised \$47 million in Series A funding to develop DeltaStem, an AI platform aiming to revolutionize human cell production for therapeutic applications, addressing challenges in purity, scalability, and reproducibility of stem cell differentiation.

Somite AI Secures \$47 Million to Revolutionize Human Cell Production with AI

Somite AI, a biotech startup, raised \$47 million in Series A funding to develop DeltaStem, an AI platform aiming to revolutionize human cell production for therapeutic applications, addressing challenges in purity, scalability, and reproducibility of stem cell differentiation.

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the significance of Somite AI's \$47 million Series A funding round for the field of regenerative medicine?

Somite AI, a startup developing AI-driven stem cell technology, secured \$47 million in Series A funding, bringing its total funding to approximately \$60 million. This round was led by Khosla Ventures and included participation from several prominent investors. The funding will support Somite's efforts to revolutionize human cell production using its AI platform, DeltaStem.

welt.de

🌐 85% Global Worthiness

May 5, 16:13

BioNTech's Oncology Push: Cancer Drug Filing Planned, Q1 Loss Reported

BioNTech, experiencing a €415.8 million net loss in Q1 2025, plans to file for U.S. approval of a uterine cancer treatment by year-end, aiming to become a leading oncology company by 2030, with a new CFO starting July 1st, 2025.

BioNTech's Oncology Push: Cancer Drug Filing Planned, Q1 Loss Reported

BioNTech, experiencing a €415.8 million net loss in Q1 2025, plans to file for U.S. approval of a uterine cancer treatment by year-end, aiming to become a leading oncology company by 2030, with a new CFO starting July 1st, 2025.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does BioNTech's Q1 2025 financial performance relate to its long-term oncology goals?

This filing represents BioNTech's strategic shift towards oncology, aiming for multiple cancer treatments by 2030. The Q1 2025 loss reflects substantial investment (€525.6 million) in advanced clinical trials for various cancer types, supporting their goal of becoming a leading biotech company in oncology. Revenue slightly decreased to €182.8 million compared to the previous year due to seasonal Covid-19 vaccine demand.

forbes.com

🌐 85% Global Worthiness

Apr 11, 19:17

Amgen's Unconventional AI Hire: Nike Data Scientist to Lead Drug Discovery

Amgen, a $151 billion pharmaceutical company, hired Sean Bruich, Nike's data science expert, as its senior vice president for AI and data in August 2023 to accelerate drug discovery and operational efficiency, reflecting the industry's growing reliance on AI and cross-industry talent acquisition.

Amgen's Unconventional AI Hire: Nike Data Scientist to Lead Drug Discovery

Amgen, a $151 billion pharmaceutical company, hired Sean Bruich, Nike's data science expert, as its senior vice president for AI and data in August 2023 to accelerate drug discovery and operational efficiency, reflecting the industry's growing reliance on AI and cross-industry talent acquisition.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does Amgen's AI strategy address the challenges and costs associated with traditional drug development, and what role does Bruich play?

Amgen's strategy highlights the growing reliance on AI in the pharmaceutical industry to address challenges in drug development. The high cost and lengthy timeline (10+ years, $2.6 billion average) of bringing a drug to market necessitate AI's potential to streamline processes and improve success rates. Bruich's experience at Google, Facebook, and Nike showcases the transferability of AI skills across sectors.

forbes.com

🌐 75% Global Worthiness

Jul 29, 16:14

Sarepta Stock Surges After FDA Lifts Hold on Elevidys

Following the FDA's decision to lift the clinical hold on its Elevidys drug, Sarepta Therapeutics' stock price rose to approximately $19 in extended trading, driven by increased revenue potential and a company restructuring plan aiming for $400 million in annual cost savings by 2026.

Sarepta Stock Surges After FDA Lifts Hold on Elevidys

Following the FDA's decision to lift the clinical hold on its Elevidys drug, Sarepta Therapeutics' stock price rose to approximately $19 in extended trading, driven by increased revenue potential and a company restructuring plan aiming for $400 million in annual cost savings by 2026.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does Sarepta's restructuring plan contribute to its potential for profitability and recovery?

The FDA's decision removes a major obstacle for Sarepta, restoring access to the full patient population for Elevidys and potentially boosting revenue significantly. The company's restructuring plan, including job cuts and program discontinuations, aims to generate $400 million in annual cost savings by 2026, improving its financial outlook.

nbcnews.com

🌐 85% Global Worthiness

Jul 8, 01:17

Family Office Investments Surge, Driven by Biotech

Family office investments surged to 60 deals in June 2025, up from 47 in May, with a notable focus on biotech, as seen in Antheia's \$56 million Series C round, aiming to improve drug access globally.

Family Office Investments Surge, Driven by Biotech

Family office investments surged to 60 deals in June 2025, up from 47 in May, with a notable focus on biotech, as seen in Antheia's \$56 million Series C round, aiming to improve drug access globally.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What were the key investment trends among family offices in June 2025, and what are their immediate implications for the involved sectors?

In June 2025, family offices significantly increased their investments, reaching 60 deals compared to 47 in May, signifying a rebound from a three-month decline. This surge included notable investments in biotech and healthcare, accounting for nine deals, showcasing the sector's appeal to these long-term investors.

forbes.com

🌐 85% Global Worthiness

Jun 11, 19:14

RFK Jr.'s Purge of CDC Vaccine Advisory Committee Condemned by Public Health Experts

On Monday, Robert F. Kennedy Jr. dismissed the CDC's vaccine advisory committee and replaced its 17 members with his own appointees, a move criticized by public health experts who warn it may lead to decreased vaccination rates and a rise in preventable illnesses, especially at a time of declining c...

RFK Jr.'s Purge of CDC Vaccine Advisory Committee Condemned by Public Health Experts

On Monday, Robert F. Kennedy Jr. dismissed the CDC's vaccine advisory committee and replaced its 17 members with his own appointees, a move criticized by public health experts who warn it may lead to decreased vaccination rates and a rise in preventable illnesses, especially at a time of declining c...

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How might Kennedy's actions affect public trust in vaccines and the efficacy of public health initiatives?

Kennedy's actions directly contradict established scientific consensus and transparent processes for vaccine recommendations. His history of anti-vaccine sentiment and promotion of conspiracy theories further exacerbates concerns about potential harm to public health. The swift replacement of experienced experts with potentially unqualified individuals raises serious questions about the future efficacy and safety of vaccine recommendations.

jpost.com

🌐 85% Global Worthiness

May 9, 01:17

Sheba Medical Center Launches US Healthcare Accelerator in Massachusetts

Sheba Medical Center is opening its first US-based healthcare startup accelerator in Massachusetts in January 2026, focusing on advanced diagnostics, digital health platforms, and workforce technologies, to connect its global network with the American healthcare market.

Sheba Medical Center Launches US Healthcare Accelerator in Massachusetts

Sheba Medical Center is opening its first US-based healthcare startup accelerator in Massachusetts in January 2026, focusing on advanced diagnostics, digital health platforms, and workforce technologies, to connect its global network with the American healthcare market.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How will this collaboration between Sheba and Massachusetts benefit both regions?

This collaboration connects Israel's medical innovation ecosystem with Massachusetts' established biotech sector, creating a global hub for healthcare startups. The initiative leverages Sheba's experience supporting over 100 startups globally and aims to accelerate AI technologies addressing global healthcare challenges. This expansion builds on Sheba's existing global network, including centers in London, Melbourne, Singapore, Berlin, and New Zealand.

fd.nl

🌐 85% Global Worthiness

Apr 27, 19:16

French Biotech Firm Develops Organ-on-a-Chip to Revolutionize Drug Testing

Netri, a French biotech startup, created a microfluidic device to test drug efficacy by measuring neuronal responses to chemical compounds, aiming to replace animal testing and reduce drug development failures; the technology is FDA-approved and seeks to overcome French stem cell regulations.

French Biotech Firm Develops Organ-on-a-Chip to Revolutionize Drug Testing

Netri, a French biotech startup, created a microfluidic device to test drug efficacy by measuring neuronal responses to chemical compounds, aiming to replace animal testing and reduce drug development failures; the technology is FDA-approved and seeks to overcome French stem cell regulations.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does Netri's 'organ-on-a-chip' technology improve the drug development process and reduce reliance on animal testing?

Netri, a Lyon-based biotech startup, developed an "organ-on-a-chip" technology to test new drugs, replacing animal testing. This small, compartmentalized device measures neuronal responses to drug compounds, predicting human reactions like pain and nausea with 80% accuracy in identifying failures seen in clinical trials. This improves drug development efficiency and reduces reliance on animal testing.

forbes.com

🌐 90% Global Worthiness

Apr 10, 01:18

Technology Supercycle Demands Proactive Adaptation

A technology supercycle driven by AI, biotechnology, and sensor technology is rapidly transforming industries and society, demanding proactive adaptation from organizations and leaders who must prioritize cultural adaptability, ethical considerations, and real-time feedback loops to navigate this un...

Technology Supercycle Demands Proactive Adaptation

A technology supercycle driven by AI, biotechnology, and sensor technology is rapidly transforming industries and society, demanding proactive adaptation from organizations and leaders who must prioritize cultural adaptability, ethical considerations, and real-time feedback loops to navigate this un...

Progress

40% Bias Score

ShareSaveArticle

Industry, Innovation, and Infrastructure

12345678

Previous 1 of 8 Next

What are the immediate and specific impacts of the current technology supercycle on various industries and societal structures?

The convergence of AI, biotechnology, and sensor technology is creating a rapid technology supercycle, impacting industries and societies globally. This unprecedented rate of change necessitates proactive adaptation, unlike previous technological shifts such as the internet boom or the Industrial Revolution. Failure to adapt risks significant disruption and irrelevance.

Showing 1 to 12 of 24 results